Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason White

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
Communications Biology|February 2, 2021
Kaiso (ZBTB33) subcellular partitioning functionally links LC3A/B, the tumor microenvironment, and breast cancer survivalSandeep K Singhal, Jung S Byun, Samson Park, et al.
Cancer Research Communications|April 21, 2023
African American Prostate Cancer Displays Quantitatively Distinct Vitamin D Receptor Cistrome-transcriptome Relationships Regulated by BAZ1AManjunath Siddappa, Shahid Hussain, Sajad A Wani, et al.
Nature Cancer|March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study resultsRashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
JCO Precision Oncology|May 18, 2026
Erratum: Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast CancerBeatriz E Adrada, Mary S Guirguis, Lei Huo, et al.
JCO Precision Oncology|December 18, 2025
Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast CancerBeatriz E Adrada, Mary S Guirguis, Lei Huo, et al.
Scientific Reports|July 11, 2024
Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerRania M Mohamed, Bikash Panthi, Beatriz E Adrada, et al.
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
Frontiers in Oncology|November 9, 2023
Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerBikash Panthi, Rania M Mohamed, Beatriz E Adrada, et al.
Cancers|July 14, 2023
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective TrialNour Abuhadra, Ryan Sun, Clinton Yam, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Communications Biology|February 2, 2021
Kaiso (ZBTB33) subcellular partitioning functionally links LC3A/B, the tumor microenvironment, and breast cancer survivalSandeep K Singhal, Jung S Byun, Samson Park, et al.
Cancer Research Communications|April 21, 2023
African American Prostate Cancer Displays Quantitatively Distinct Vitamin D Receptor Cistrome-transcriptome Relationships Regulated by BAZ1AManjunath Siddappa, Shahid Hussain, Sajad A Wani, et al.
Nature Cancer|March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study resultsRashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
JCO Precision Oncology|May 18, 2026
Erratum: Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast CancerBeatriz E Adrada, Mary S Guirguis, Lei Huo, et al.
JCO Precision Oncology|December 18, 2025
Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast CancerBeatriz E Adrada, Mary S Guirguis, Lei Huo, et al.
Scientific Reports|July 11, 2024
Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerRania M Mohamed, Bikash Panthi, Beatriz E Adrada, et al.
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
Frontiers in Oncology|November 9, 2023
Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerBikash Panthi, Rania M Mohamed, Beatriz E Adrada, et al.
Cancers|July 14, 2023
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective TrialNour Abuhadra, Ryan Sun, Clinton Yam, et al.
Pageof 11